Increased protein-conjugated acrolein and amyloid-β40/42 ratio in plasma of patients with mild cognitive impairment and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 32, Issue 1, 2012, Pages 33-41

  Waragai, Masaaki ^a   Yoshida, Madoka ^b   Mizoi, Mutsumi ^b   Saiki, Ryotaro ^b   Kashiwagi, Keiko ^c   Takagi, Kiyoshi ^d   Arai, Hiroyuki ^e   Tashiro, Jun ^a   Hashimoto, Makoto ^f   Iwai, Naomichi ^a   Uemura, Kenichi ^a   Igarashi, Kazuei ^b  

^a Matsudo City Hospital   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c CHIBA INSTITUTE OF SCIENCE   (Japan)

^d Kashiwatanaka Hospital   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Alzheimer's disease; amyloid ; magnetic resonance imaging; plasma biomarker; protein conjugated acrolein; white matter hyperintensity

Indexed keywords

ACROLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; ALZHEIMER DISEASE; ARTICLE; CELL DAMAGE; CONJUGATION; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; WHITE MATTER;

EID: 84867617173     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-120253     Document Type: Article

References (40)

1. Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007) Hydrogen peroxide: A metabolic by-product or a common mediator of aging signals? Nat Rev Mol Cell Biol 8, 722-728.
2. Sharmin S, Sakata K, Kashiwagi K, Ueda S, Iwasaki S, Shirahata A, Igarashi K (2001) Polyamine cytotoxicity in the presence of bovine serum amine oxidase. Biochem Biophys Res Commun 282, 228-235.
3. Yoshida M, Tomitori H, Machi Y, Hagihara M, Higashi K, Goda H, Ohya T, Niitsu M, Kashiwagi K, Igarashi K (2009) Acrolein toxicity: Comparison with reactive oxygen species. Biochem Biophys Res Commun 378, 313-318.
4. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E (1998) Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 273, 16058-16066.
5. Igarashi K, Kashiwagi K (2010) Modulation of cellular function by polyamines. Int J Biochem Cell Biol 42, 39-51.
6. Tomitori H, Usui T, Saeki N, Ueda S, Kase H, Nishimura K, Kashiwagi K, Igarashi K (2005) Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke 36, 2609-2613.
7. Yoshida M, Higashi K, Kobayashi E, Saeki N, Wakui K, Kusaka T, Takizawa H, Kashiwado K, Suzuki N, Fukuda K, Nakamura T, Watanabe S, Tada K, Machi Y, Mizoi M, Toida T, Kanzaki T, Tomitori H, Kashiwagi K, Igarashi K (2010) Correlation between images of silent brain infarction, carotid atherosclerosis and white matter hyperintensity, and plasma levels of acrolein, IL-6 and CRP. Atherosclerosis 211, 475-479.
8. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
9. Drachman DA (2006) Aging of the brain, entropy, and Alzheimer disease. Neurology 67, 1340-1352.
10. Norderg A, Rinne JO, Kadir A, L°angstr̈om B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
11. Risacher SL, Shen L, West JD, Kim S, McDonald BC, Berckett LA, Harvey DJ, Jack CR Jr, Weiner MV, Saykin AJ, Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010) Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiol Aging 31, 1401-1418.
12. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid -protein levels. Arch Neurol 60, 958-964.
13. Sob́ow T, Flirski M, Kloszewska I, Liberski PP (2005) Plasma levels of A- peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp 65, 117-124.
14. Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y-M, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzherimer's disease. Alzheimers Dement 5, 18-29.
15. Le Bastard N, Leurs J, BlommeW, De Deyn PP, Engelborghs S (2010) Plasma amyloid- forms in Alzheimer's disease and non-Alzheimer's disease patients. J Alzheimers Dis 21, 291-301.
16. Mehta PD, Pirttil̈a T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid - proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
17. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Yonkin SG (2007) Association of low plasma A-42/A-40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
18. Lui JK, Laws SM, Li Q-X, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, Faux NG, Foster J, Flowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, AIBL Research Goup (2010) Plasma amyloid- as a biomarker in Alzheimer's disease: The AIBL study of aging. J Alzheimers Dis 20, 1233-1242.
19. YaffeK,Weston A, Graff-Radford NR, Stafferfield S, Simoinscick EM,Younkin SG,Younkin LH,Kuller L,Ayonayon NN, Ding J, Harris TB (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266.
20. Devanand DP, Schurf N, Stern Y, Parsey R, Pelton GH, Mehta P, Mayeux R (2011) Plasma A- and PET PiB binding are inversely related in mild cognitive impairment. Neurology 77, 125-131.
21. Calingasan NY, Uchida K, Gibson GE (1999) Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72, 751-756.
22. Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic Biol Med 48, 1570-1576.
23. Singh M, Nam DT, Arseneault M, Ramassamy C (2010) Role of by-products of lipid oxidation in Alzheimer's disease brain: A focus on acrolein. J Alzheimers Dis 21, 741-756.
24. Nam DT, Arseneault M, Murthy V, Ramassamy C (2010) Potential role of acrolein in neurodegeneration and in Alzheimer's disease. Curr Mol Pharmacol 3, 66-78.
25. Holmes C, Cunningham C, Zotaba E, Culliford D, Perry VH (2011) Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 77, 212-218.
26. Waragai M, Okumura N, Furukawa K, Tashiro M, Furumoto S, Funaki Y, Kato M, Iwata R, Yanai K, Kudo Y, Arai H (2009) Comparison study of amyloid PET and voxelbased morphometry analysis in mild cognitive impairment and Alzheimer's disease. J Neurol Sci 285, 100-108.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
28. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
29. Igarashi K, Kashiwagi K (2011) Protein-conjugated acrolein as a biochemical marker of brain infarction. Mol Nutr Food Res 55, 1332-1341.
30. Igarashi K, Ueda S, Yoshida K, Kashiwagi K (2006) Polyamines in renal failure. Amino Acids 31, 477-483.
31. O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, Lupo PJ, Reisch JS, Doody R (2008) Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: A Texas Alzheimer's research consortium study. Arch Neurol 65, 1091-1095.
32. Shinohara Y, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Yamaguchi T, Okudera T (2007) Effect of the Ca antagonist nilvadipine on stroke occurrence or recurrence and extension of asymptomatic cerebral infarction in hypertensive patients with or without history of stroke (PICA Study). 1. Design and results at enrollment. Cerebrovasc Dis 24, 202-209.
33. Gao S, Hendrie HC, Hall KS, Hui S (1998) The relationship between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. Arch Gen Psychiatry 55, 809-815.
34. Ashburner J, Friston KJ (2000) Voxel-based morphometry - the methods. Neuroimage 11, 805-821.
35. Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, Asada T, Iwabuchi S, SamejimaH(2005)Voxelbased morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382, 269-274.
36. Ellenius J, Groth T, Lindahl B, Wallentin L (1997) Early assessment of patients with suspected acute myocardial infarction by biochemical monitoring and neural network analysis. Clin Chem 43, 1919-1925.
37. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring -amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199.
38. Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S (1997) Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 28, 1932-1939.
39. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D'Agostino RB, DeCarli C (2006) Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 63, 246-250.
40. Li X, Shimizu S, Jibiki I,Watanabe K, Kubota T (2010) Correlations between Z-scores of VSRAD and regional cerebral blood flow of SPECT in patients with Alzheimer's disease and mild cognitive impairment. Psychiatry Clin Neurosci 64, 284-292.